Cysmethynil

Research use only, not for human use.

Cysmethynil is an indole-based time-dependent inhibitor of Icmt with antitumour activity and inhibitory effects on RAS membrane-binding and EGF signalling.

Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research.

Cell Viability AssayCell Line:PC3 cells Concentration:20-30 μM cysmethynil Incubation Time:1-6 days Result:Resulted in a dose- and time-dependent reduction in the number of viable PC3 cells.

Animal Model:6 week-old SCID mice with SiHa cells in the mice flank Dosage:20 mg/kg (single; combination with Paclitaxel or Doxorubicin)Administration:intraperitoneal injection; three times a week; 2 weeks Result: Decreased in tumor size when treated with Cys alone, or Cysmethynil+Paclitaxel(HY-B0015)/Cysmethynil+ Doxorubicin(HY-15142A) .Animal Model:SCID mice with PC3 cells in a xenograft model Dosage:0.1 mg/g or 0.2 mg/g Cysmethynil Administration:intraperitoneal injection; every 48 h; 28 days Result:Decreased in tumor size when treated with both doses of cysmethynil.

——

Autophagy

Autophagy

Autophagy | Ras

——

——

851636-83-4

376.53

C25H32N2O

>98% (HPLC)

——

O=C(N)CC1=CN(C2=CC=C(C=C21)C=3C=CC=C(C3)C)CCCCCCCC

——

(-20℃)

With Ice Pack

≥ 2 years